Catarina Xavier1, Anneleen Blykers1, Damya Laoui2,3, Evangelia Bolli2,3, Ilse Vaneyken1,4, Jessica Bridoux1, Henri Baudhuin1, Geert Raes2,3, Hendrik Everaert4, Kiavash Movahedi2,3, Jo A Van Ginderachter2,3, Nick Devoogdt1, Vicky Caveliers1,4, Tony Lahoutte1,4, Marleen Keyaerts5,6. 1. In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium. 2. Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium. 3. Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium. 4. Nuclear Medicine Department (NUCG), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. 5. In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium. marleen.keyaerts@vub.be. 6. Nuclear Medicine Department (NUCG), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. marleen.keyaerts@vub.be.
Abstract
PURPOSE: Macrophage mannose receptor (MMR, CD206) expressing tumor-associated macrophages (TAM) are protumorigenic and was reported to negatively impact therapy responsiveness and is associated with higher chances of tumor relapse following multiple treatment regimens in preclinical tumor models. Since the distribution of immune cells within the tumor is often heterogeneous, sampling "errors" using tissue biopsies will occur. In order to overcome this limitation, we propose positron emission tomography (PET)/X-ray computed tomography (CT) imaging using 68Ga-labeled anti-MMR single-domain antibody fragment (sdAb) to assess the presence of these protumorigenic TAM. PROCEDURES: Cross-reactive anti-MMR-sdAb was produced according to good manufacturing practice (GMP) and conjugated to p-SCN-Bn-NOTA bifunctional chelator for 68Ga-labeling. Biodistribution and PET/CT studies were performed in wild-type and MMR-deficient 3LL-R tumor-bearing mice. Biodistribution data obtained in mice were extrapolated to calculate radiation dose estimates for the human adult using OLINDA software. A 7-day repeated dose toxicity study for NOTA-anti-MMR-sdAb was performed in healthy mice up to a dose of 1.68 mg/kg. RESULTS: [68Ga]Ga-NOTA-anti-MMR-sdAb was obtained with 76 ± 2 % radiochemical yield, 99 ± 1 % radiochemical purity, and apparent molar activity of 57 ± 11 GBq/μmol. In vivo biodistribution analysis showed fast clearance via the kidneys and retention in MMR-expressing organs and tumor, with tumor-to-blood and tumor-to-muscle ratios of 6.80 ± 0.62 and 5.47 ± 1.82, respectively. The calculated effective dose was 0.027 mSv/MBq and 0.034 mSv/MBq for male and female, respectively, which means that a proposed dose of 185 MBq in humans would yield a radiation dose of 5.0 and 6.3 mSv to male and female patients, respectively. In the toxicity study, no adverse effects were observed. CONCLUSIONS: Preclinical validation of [68Ga]Ga-NOTA-anti-MMR-sdAb showed high specific uptake of this tracer in MMR-expressing TAM and organs, with no observed toxicity. [68Ga]Ga-NOTA-anti-MMR-sdAb is ready for a phase I clinical trial.
PURPOSE: Macrophage mannose receptor (MMR, CD206) expressing tumor-associated macrophages (TAM) are protumorigenic and was reported to negatively impact therapy responsiveness and is associated with higher chances of tumor relapse following multiple treatment regimens in preclinical tumor models. Since the distribution of immune cells within the tumor is often heterogeneous, sampling "errors" using tissue biopsies will occur. In order to overcome this limitation, we propose positron emission tomography (PET)/X-ray computed tomography (CT) imaging using 68Ga-labeled anti-MMR single-domain antibody fragment (sdAb) to assess the presence of these protumorigenic TAM. PROCEDURES: Cross-reactive anti-MMR-sdAb was produced according to good manufacturing practice (GMP) and conjugated to p-SCN-Bn-NOTA bifunctional chelator for 68Ga-labeling. Biodistribution and PET/CT studies were performed in wild-type and MMR-deficient 3LL-R tumor-bearing mice. Biodistribution data obtained in mice were extrapolated to calculate radiation dose estimates for the human adult using OLINDA software. A 7-day repeated dose toxicity study for NOTA-anti-MMR-sdAb was performed in healthy mice up to a dose of 1.68 mg/kg. RESULTS: [68Ga]Ga-NOTA-anti-MMR-sdAb was obtained with 76 ± 2 % radiochemical yield, 99 ± 1 % radiochemical purity, and apparent molar activity of 57 ± 11 GBq/μmol. In vivo biodistribution analysis showed fast clearance via the kidneys and retention in MMR-expressing organs and tumor, with tumor-to-blood and tumor-to-muscle ratios of 6.80 ± 0.62 and 5.47 ± 1.82, respectively. The calculated effective dose was 0.027 mSv/MBq and 0.034 mSv/MBq for male and female, respectively, which means that a proposed dose of 185 MBq in humans would yield a radiation dose of 5.0 and 6.3 mSv to male and female patients, respectively. In the toxicity study, no adverse effects were observed. CONCLUSIONS: Preclinical validation of [68Ga]Ga-NOTA-anti-MMR-sdAb showed high specific uptake of this tracer in MMR-expressing TAM and organs, with no observed toxicity. [68Ga]Ga-NOTA-anti-MMR-sdAb is ready for a phase I clinical trial.
Authors: F A Stewart; A V Akleyev; M Hauer-Jensen; J H Hendry; N J Kleiman; T J Macvittie; B M Aleman; A B Edgar; K Mabuchi; C R Muirhead; R E Shore; W H Wallace Journal: Ann ICRP Date: 2012-02
Authors: Kiavash Movahedi; Steve Schoonooghe; Damya Laoui; Isabelle Houbracken; Wim Waelput; Karine Breckpot; Luc Bouwens; Tony Lahoutte; Patrick De Baetselier; Geert Raes; Nick Devoogdt; Jo A Van Ginderachter Journal: Cancer Res Date: 2012-06-19 Impact factor: 12.701
Authors: Anneleen Blykers; Steve Schoonooghe; Catarina Xavier; Kevin D'hoe; Damya Laoui; Matthias D'Huyvetter; Ilse Vaneycken; Frederik Cleeren; Guy Bormans; Johannes Heemskerk; Geert Raes; Patrick De Baetselier; Tony Lahoutte; Nick Devoogdt; Jo A Van Ginderachter; Vicky Caveliers Journal: J Nucl Med Date: 2015-06-11 Impact factor: 10.057
Authors: Pablo Scodeller; Lorena Simón-Gracia; Sergei Kopanchuk; Allan Tobi; Kalle Kilk; Pille Säälik; Kaarel Kurm; Mario Leonardo Squadrito; Venkata Ramana Kotamraju; Ago Rinken; Michele De Palma; Erkki Ruoslahti; Tambet Teesalu Journal: Sci Rep Date: 2017-11-07 Impact factor: 4.379
Authors: Dangshe Ma; Jessica R Kirshner; Richard Tavaré; Makenzie Danton; Jason T Giurleo; Sosina Makonnen; Carlos Hickey; Tomas C Arnold; Marcus P Kelly; Fanny Fredriksson; Karina Bruestle; Aynur Hermann; Erica Ullman; Kurt H Edelmann; Terra Potocky; Drew Dudgeon; Nikunj B Bhatt; Mikhail Doubrovin; Thomas Barry; Christos A Kyratsous; Cagan Gurer; Naxin Tu; Hans Gartner; Andrew Murphy; Lynn E Macdonald; Jon Popke; Akiva Mintz; Adam Griesemer; William C Olson; Gavin Thurston Journal: Cancer Immunol Res Date: 2022-10-04 Impact factor: 12.020
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06